Uric acid levels and atrial fibrillation in hypertensive patients

Internal Medicine

Volumn 50, Issue 8, 2011, Pages 799-803

  Liu, Tong ^a   Zhang, Xiaowei ^a   Korantzopoulos, Panagiotis ^b   Wang, Shaohua ^a   Li, Guangping ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atrial fibrillation; Hypertension; Inflammation; Oxidative stress; Uric acid

Indexed keywords

CREATININE; URIC ACID;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART VENTRICLE SEPTUM; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PILOT STUDY; THICKNESS; URIC ACID BLOOD LEVEL;

ADULT; AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CREATININE; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; HEART ATRIA; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTORS; URIC ACID; VENTRICULAR FUNCTION, LEFT;

EID: 79955566796     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4587     Document Type: Article

References (27)

1. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 27: 13-24, 2009.
2. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 160: 797-805, 2000.
3. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 21: 1064-1070, 2010.
4. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115: 135-143, 2007.
5. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol 18: 1222-1228, 2007.
6. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: A systematic review and metaanalysis of randomized clinical trials and observational studies. Int J Cardiol 126: 160-170, 2008.
7. Burashnikov A, Antzelevitch C. New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol 7: 139-148, 2010.
8. Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol Rev 17: 216-221, 2009.
9. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 93: 621-635, 2009.
10. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 62: 633-644, 2006.
11. Gagliardi ACM, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 202: 11-17, 2009.
12. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des 11: 4145-4151, 2005.
13. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 17: 409-414, 2007.
14. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 25: 39-42, 2005.
15. Corry DB, Tuck ML. Uric acid and the vasculature. Curr Hypertens Rep 8: 116-119, 2006.
16. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11: 444-452, 2009.
17. Levy S, Camm AJ, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 5: 119-122, 2003.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999.
19. Dun W, Boyden PA. Aged atria: electrical remodeling conducive to atrial fibrillation. J Interv Card Electrophysiol 25: 9-18, 2009.
20. Solun B, Marcoviciu D, Dicker D. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke? Eur J Intern Med 20: 125-131, 2009.
21. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 51: 1-11, 2008.
22. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 1: 62-73, 2008.
23. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53: 1652-1657, 2007.
24. Letsas KP, Korantzopoulos P, Filippatos GS, et al. Uric acid elevation in atrial fibrillation. Hellenic J Cardiol 51: 209-213, 2010.
25. Tamariz L, Agarwal S, Soliman E, et al. Serum uric acid as a predictor of incident atrial fibrillation: The Atherosclerosis Risk in Communities Study [Abstract]. American College of Cardiology 2010 Congress. J Am Coll Cardiol 2010; Vol.55, issue 10A, Abstract No. A7.E62.
26. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821, 2008.
27. Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112: 1266-1273, 2005.